Xilio Therapeutics, Inc. (XLO)

Market Cap	52.31M +24.6%
Revenue (ttm)	64.09M +327.3%
Net Income	-21.83M
EPS	-3.32
Shares Out	6.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,395
Open	7.49
Previous Close	8.03
Day's Range	7.49 - 8.07
52-Week Range	6.47 - 12.32
Beta	-0.12
Analysts	Buy
Price Target	18.00 (+126.42%)
Est. Earnings	Nov 16, 2026

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 76
• Stock Exchange: Nasdaq
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Financial Performance

In 2025, Xilio Therapeutics's revenue was $43.77 million, an increase of 589.88% compared to the previous year's $6.34 million. Losses were -$35.04 million, -39.84% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for XLO stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 126.42% from the latest price.

Price Target

$18.0

(126.42% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 2, 2026

Data Sources Report a data error